Clinical Trials Logo

Clinical Trial Details — Status: Recruiting

Administrative data

NCT number NCT03559114
Other study ID # 0785
Secondary ID
Status Recruiting
Phase Phase 3
First received
Last updated
Start date July 19, 2018
Est. completion date December 2027

Study information

Verified date May 2024
Source Sunnybrook Health Sciences Centre
Contact Farhad Pirouzmand, MD, MSc, FRCSC
Phone 416-480-6100
Email farhad.pirouzmand@sunnybrook.ca
Is FDA regulated No
Health authority
Study type Interventional

Clinical Trial Summary

This is a pilot study, phase III, multi-centre, double blind, randomized controlled trial of patients with traumatic brain injury (TBI).


Description:

Patients with severe brain injury are at risk for developing blood clots in their legs, which can travel to the lungs. This potentially serious complication is known as venous thromboembolism (VTE). Anticoagulants are commonly used to prevent VTE in hospital patients. However, in patients with major head injury, anticoagulant prevention is commonly delayed for the fear that it can potentially lead to further bleeding in the brain. Another method that aims to prevent blood clots involves the use of sequential compression device (SCD) that compress the legs and increase the flow of blood in the leg veins. This study will compare results from patients who receive the SCDs only to those who receive both SCD and anticoagulants. The outcome of this study will provide information about how best to prevent blood clots while not increase brain bleeding after head injury.


Recruitment information / eligibility

Status Recruiting
Enrollment 1100
Est. completion date December 2027
Est. primary completion date December 2026
Accepts healthy volunteers No
Gender All
Age group 18 Years and older
Eligibility Inclusion Criteria The pragmatic nature of this study seeks to include all consecutive patients presenting with significant TBI, regardless of whether ICB is evident at presentation. Inclusion criteria are the following: i) Patients with severe TBI defined as GCS of =8, or ii) Patients with moderate TBI defined as GCS = 9-12, admitted to ICU, with at least some ICB present on initial CT scan and any of the following: 1. Requiring invasive mechanical ventilation at the time of screening 2. Increased ICB on repeat CT scan compared to initial CT scan iii) Upon randomization the patient will be able to receive the first dose of study drug in the first 3 calendar days from the time of injury iv) = 18 years of age Exclusion Criteria All participants meeting any of the following exclusion criteria at baseline will be excluded from participation in this study: i) Known Hypersensitivity to FRAGMIN (Dalteparin), or its constituents including benzyl alcohol or to other low molecular weight heparins and/or heparins or pork products ii) Known history of confirmed or suspected immunologically-mediated heparin-induced thrombocytopenia (delayed-onset severe thrombocytopenia), and/or in patients with a known history of a positive in vitro platelet-aggregation test in the presence of FRAGMIN (Dalteparin) is positive iii) Known septic endocarditis iv) Uncontrollable active bleeding v) Known major blood clotting disorders vi) Known acute gastroduodenal ulcer (with active bleeding) vii) Severe uncontrolled hypertension (i.e. BP>210 despite medications) viii) Known diabetic or hemorrhagic retinopathy ix) Anticipated to be unable to receive SCD on at least one lower extremity due to nature of injuries for duration of intervention period x) Presence of another confounding factor that can adequately explain the poor GCS at time of presentation (e.g. drug toxicity, seizure) xi) Known presence of irreversible coagulopathies xii) Known Pregnancy xiii) Participants extremely low weight (<45 kg), or extremely high weight (>120kg) xiv) Not expected to survive more than 48 hours from admission

Study Design


Intervention

Drug:
Dalteparin
Dalteparin in prophylactic doses administered daily if screening criteria are satisfied.
Saline
Saline in prophylactic doses administered daily if screening criteria are satisfied.

Locations

Country Name City State
Canada Foothills Medical Centre Calgary Alberta
Canada Royal Alexandra Hospital Edmonton Alberta
Canada University of Alberta Hospital Edmonton Alberta
Canada Queen Elizabeth II Health Sciences Centre Halifax Nova Scotia
Canada Hamilton Health Sciences Centre Hamilton Ontario
Canada Kingston General Hospital Kingston Ontario
Canada The Ottawa Hospital Ottawa Ontario
Canada Hopital de L'Enfant-Jesus Quebec
Canada Royal University Hospital Saskatoon Saskatchewan
Canada Sunnybrook Health Science Centre Toronto Ontario
Canada Unity Health Toronto Toronto Ontario
Canada Vancouver General Hospital Vancouver British Columbia

Sponsors (3)

Lead Sponsor Collaborator
Sunnybrook Health Sciences Centre Canadian Institutes of Health Research (CIHR), Sunnybrook Research Institute

Country where clinical trial is conducted

Canada, 

Outcome

Type Measure Description Time frame Safety issue
Primary Clinically important VTE Composite outcome of clinically-important VTE within 7±1 days after randomization defined as any of:
Symptomatic, objectively-confirmed pulmonary embolism (PE), or
Symptomatic, objectively-confirmed, proximal leg deep vein thrombosis (DVT), or
Proximal (above knee) leg DVT on compression ultrasonography on Day 7±1
8 days
Secondary Clinically-important ICB (Intracranial bleeding) progression Clinically-important ICB progression within 7±1 days after randomization , as defined by having (1) any increase in volume of blood in the brain on any CT scan within 7±1 days relative to initial CT scan on Day 0* AND (2) clinical worsening within 24 hours of this CT scan, defined by one or more of the following:
Surgical intervention related to increased ICB after Day 0 (craniotomy/craniectomy, ICP monitor, external ventricular drain)
Decrease of GCS (Glasgow Coma Scale) by at least 2 points not related to sedation
Increase in ICP >5 mmHg on 2 occasions at least 6 hours apart despite medical therapy (if ICP monitor is in place)
Death
7 days
Secondary Objectively confirmed new or progressing ICB on radiology, Assessed by comparing the initial brain CT (Day 0) to that performed within 8±1 days following randomization (or most recent prior to death). 8 days
Secondary 180-day Mortality Mortality at 180 days 180 days
Secondary 7-day Mortality Mortality at 7 days 7 days
Secondary 30-day Mortality Mortality at 30 days 30 days
Secondary Delayed VTE after day 7 Any clinically important VTE occurring between Day 8 to Day 30 detected by treating clinicians 30 days
Secondary Functional neurological outcome at day 30 as measured by Glasgow Outcome Scale Extended Glasgow Outcome Scale Extended (GOSE) at Day 30±5 by phone interview. 30 days
Secondary Functional neurological outcome at day 180 as measured by Glasgow Outcome Scale Extended Glasgow Outcome Scale Extended (GOSE) at Day 180±14 by phone interview. 180 days
Secondary Quality of life outcome at 30 days as measured by the EuroQol5D EQ-5D (EuroQol 5D) at Day 30±5 by phone interview. 30 days
Secondary Quality of life outcome at 180 days as measured by the EuroQol5D EQ-5D (EuroQol 5D) at Day 180±14 by phone interview. 180 days
See also
  Status Clinical Trial Phase
Terminated NCT03052712 - Validation and Standardization of a Battery Evaluation of the Socio-emotional Functions in Various Neurological Pathologies N/A
Recruiting NCT05503316 - The Roll of Balance Confidence in Gait Rehabilitation in Persons With a Lesion of the Central Nervous System N/A
Completed NCT04356963 - Adjunct VR Pain Management in Acute Brain Injury N/A
Completed NCT03418129 - Neuromodulatory Treatments for Pain Management in TBI N/A
Terminated NCT03698747 - Myelin Imaging in Concussed High School Football Players
Recruiting NCT05130658 - Study to Improve Ambulation in Individuals With TBI Using Virtual Reality -Based Treadmill Training N/A
Recruiting NCT04560946 - Personalized, Augmented Cognitive Training (PACT) for Service Members and Veterans With a History of TBI N/A
Completed NCT05160194 - Gaining Real-Life Skills Over the Web N/A
Recruiting NCT02059941 - Managing Severe Traumatic Brain Injury (TBI) Without Intracranial Pressure Monitoring (ICP) Monitoring Guidelines N/A
Recruiting NCT03940443 - Differences in Mortality and Morbidity in Patients Suffering a Time-critical Condition Between GEMS and HEMS
Recruiting NCT03937947 - Traumatic Brain Injury Associated Radiological DVT Incidence and Significance Study
Completed NCT04465019 - Exoskeleton Rehabilitation on TBI
Recruiting NCT04530955 - Transitioning to a Valve-Gated Intrathecal Drug Delivery System (IDDS) N/A
Recruiting NCT03899532 - Remote Ischemic Conditioning in Traumatic Brain Injury N/A
Suspended NCT04244058 - Changes in Glutamatergic Neurotransmission of Severe TBI Patients Early Phase 1
Completed NCT03307070 - Adapted Cognitive Behavioral Treatment for Depression in Patients With Moderate to Severe Traumatic Brain Injury N/A
Recruiting NCT04274777 - The Relationship Between Lipid Peroxidation Products From Traumatic Brain Injury and Secondary Coagulation Disorders
Withdrawn NCT05062148 - Fundamental and Applied Concussion Recovery Modality Research and Development: Applications for the Enhanced Recovery N/A
Withdrawn NCT04199130 - Cognitive Rehabilitation and Brain Activity of Attention-Control Impairment in TBI N/A
Withdrawn NCT03626727 - Evaluation of the Efficacy of Sodium Oxybate (Xyrem®) in Treatment of Post-traumatic Narcolepsy and Post-traumatic Hypersomnia Early Phase 1